move, but some had ascites, pleural effusion, jaundice, dyspnea (3-10%), and used narcotic (13%). At first visit, as old as age 97 received care (mean age 54.8ϩ/Ϫ14.3; ranged 1-97), and lung, hepatobiliary, colon, gastric, breast and pancreatic cancer were comprised of 80% of cancers. Among these about 40-50% had poor performance status . CONCLUSIONS: In consideration of the size of the center and non-insured, offering cytostatic therapy received with remarkable attention by the patients previously treated with cytotoxic therapy. Further research is needed to investigate cons and pros of cytostatic therapy. 
PCN114 DEFINING REGULATORY SUCCESS FOR PATIENT-REPORTED OUTCOMES (PROS) IN ONCOLOGY
OBJECTIVES: FDA and EMA have created guidelines for PRO label claims. However, there have been few PRO-based label claims in oncology (Gnanasakthy, et al., 2012) since the release of the FDA guidelines. The objective of this research was to explore factors that might predict regulatory success for PROs. We developed a regulatory success gradient, and used factors based on literature review, expert interviews, and the FDA Guidances to predict success. METHODS: Using a case-control approach, 10 oncology medications with PRO labels came from two sources: 1) a review of PROs in oncology labels (Gondek et al, 2007) , and 2) a proprietary database (http://www.mapi-prolabels.org/) containing a list of PRO-based labels. Six controls were oncology medications with the same indication and mechanism of action, but without PRO data in the label. Regulatory success was defined from none (no PRO in the label), through minimal, mild, and moderate, to great success (PRO labeling in the indication section). Independent factors, derived from literature review, expert interviews, and the PRO Guidances, possibly related to regulatory success included conceptual fit, study quality, conformity to PRO Guidance (content validity), psychometrics score, and other PRO characteristics, were evaluated. RESULTS: No medication achieved great PRO labeling success. Only three medications achieved moderate regulatory success, seven achieved mild, and five achieved minimal success. None of the factors identified as potentially related to regulatory success were significantly correlated with it (Spearman correlations): Other PRO Characteristics (0.33), Conceptual Fit (0.09), Study Quality (-0.13), Psychometrics (-0.18), and Conformity to the PRO Guidance (0-0.02). CONCLUSIONS: Despite widespread use of PROs in oncology, very few labels actually include PRO-based results, and furthermore, no medications achieved great success and only three moderate success in labeling. Based on our regulatory success gradient, driving factors leading to regulatory success have yet to be identified. 
PCN115 QUALITY OF LIFE IN LUNG CANCER PATIENTS DURING ADJUVANT OR PALLIATIVE CHEMOTHERAPY

OBJECTIVES:
Lung cancer is one of the most common high incidence and mortality cancers. Many lung cancer patients (LCPs) receive chemotherapy not only for curative treatment, but also to palliate symptoms and maintain or even improve their quality of life (QOL). Though the impact of substances and duration of chemotherapy on progression-free and overall survival is intensively investigated, there is currently only little knowledge on patients' QOL in regard to the number of CT-lines administered. METHODS: By means of computer-based patient-reported outcome monitoring LCPs receiving ambulant chemotherapy (adjuvant or palliative) completed the internationally validated EORTC QLQ-C30, supplemented by two additional questions concerning taste alterations. Statistical analysis comprised mixed linear models to calculate change rates over time and differences between chemotherapy lines. RESULTS: A total of 175 LCPs (32% female, on average 68 years old (Ϯ 10.4 SD) and 5 (Ϯ 4.5 SD) assessments/patient) participated in repeated QOL-assessment during ambulant chemotherapy administration. 
PCN116 MAPPING FACT-P TO EQ-5D IN A LARGE CROSS-SECTIONAL STUDY OF METASTATIC CASTRATE-RESISTANT PROSTATE CANCER PATIENTS
Janssen-Cilag, London, UK
Appropriate utility values for disease states in metastatic castration-resistant prostate cancer (mCRPC) have been contentious in recent economic models submitted to NICE and other HTA bodies. The validity of mapping algorithms beyond the range of original data in less symptomatic patients and the evolution of utility once life-extending treatments have failed, were both considered areas of uncertainty.
OBJECTIVES:
To construct and validate a prediction model of preference-adjusted health status (EQ-5D) for metastatic castration-resistant prostate cancer (mCRPC) patients using FACT-P (Functional Assessment of Cancer Therapy-Prostate).
METHODS:
Observational study conducted in 47 centres across 6 countries (Belgium, France, Germany, Sweden, The Netherlands, UK) collected HRQoL data for 699 patients with confirmed mCRPC and documented disease progression. Utility values were derived from EQ-5D profiles based on a UK-specific EQ-5D value set (1). Predictive validity of the 5 FACT-P subscales, patient demographics, co-morbidities and prior chemotherapy for utility values was tested using ordinary least square (OLS), median, Gamma and Tobit multivariate regression models. RESULTS: At the time of assessment, mean age, mean time since diagnosis and failure on androgendeprivation therapy were 72.1, 6.6 and 4.1 years respectively; 32% of patients were treated with chemotherapy, 24% had prior chemotherapy, and 43% were chemotherapy naive. At diagnosis, 35.9% of patients had metastases and 84.1% had Gleason score Ն7. Mean FACT-P and EQ-5D utility were 104.0 and 0.67 respectively. OLS-regression was the best-performing model, explaining 61% of the observed EQ-5D variation. All FACT-P subscales were significantly predictive. The physical (coefficientϭ0.023,pϽ0.0001) and functional (0.011,pϽ0.0001) well-being subscales had the highest explanatory value. Age, co-morbidities and prior chemotherapy did not add additional explanatory value. CONCLUSIONS: The developed algorithms enable translation of cancer-specific health-related quality of life measures to preference-adjusted health status in mCRPC-patients. Findings will help to develop health status adjustments in cost-utility analyses used in future HTA's. 
PCN117 QUALITY OF LIFE IN PATIENTS WITH MALIGNANT ASCITES AFTER TREATMENT WITH CATUMAXOMAB: A MULTICENTER PHASE II/III STUDY COMPARING PARACENTESIS PLUS CATUMAXOMAB WITH PARACENTESIS ALONE
OBJECTIVES:
Malignant ascites (MA) is associated with poor prognosis and limited palliative therapeutic options. Therefore a change in patients' health-related quality of life (HRQoL) is of particular importance to demonstrate added value of a new treatment to the patient-reported outcomes (PRO). Moreover how fast the change occurs can be as important as the simple occurrence of a meaningful change in HRQoL. Following demonstration of superiority on puncture-free survival of catumaxomab plus paracentesis vs paracentesis alone, this study aimed to compare time to deterioration in HRQoL between both treatment groups by using survival analysis techniques. METHODS: In a randomized, multi-center, phase II/III study in patients with MA, HRQoL was measured by using the European Organization for A430 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 -A 5 7 5
